Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life PLC hails "major accomplishment" as nasally administered antibody shows potential to treat degenerative diseases such as MS
02:43am, Wednesday, 26'th May 2021
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said its breakthrough fully-human monoclonal antibody “induces immunomodulatory effects capable of providing clinical benefit” when administered n
NEW YORK and LONDON, May 26, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeuti
TLSA Stock Price: Over 8% Increase Pre-Market Explanation
06:22am, Tuesday, 25'th May 2021
The stock price of Tiziana Life Sciences PLC (NASDAQ: TLSA) increased by over 8% pre-market. This is why it happened.
Tiziana Life Starts Testing Nasally Administered Foralumab in Multiple Sclerosis Patients
06:16am, Tuesday, 25'th May 2021
Under an individual patient expanded access program, Tiziana Life Sciences plc (NASDAQ: TLSA) has dosed the first patient with secondary progressive multiple sclerosis with nasally administered fo
Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) said it has begun treating a patient with secondary progressive multiple sclerosis using nasally-administered Foralumab, the company's fully-human ant
NEW YORK and LONDON, May 25, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeuti
Tiziana Life Sciences confident of advancing drug development pipeline
09:15am, Tuesday, 18'th May 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS) said it is confident that it is well positioned to advance its drug development programs "to their next respective value inflection points". Final re
Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
02:00am, Friday, 07'th May 2021
NEW YORK and LONDON, May 07, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology, inflammation and inf
Tiziana Life Sciences seeks clinical partner in Asia to progress work on liver cancer treatment
04:48am, Wednesday, 05'th May 2021
Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) announced an agreement with Takanawa Japan for a strategic business development plan to identify a clinical partner in Japan and other Asian countries
NEW YORK and LONDON, May 05, 2021 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / LSE: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeut
Tiziana Life Sciences says Accustem Sciences business will be spin out on Nasdaq
08:45am, Tuesday, 13'th Apr 2021
Tiziana Life Sciences PLC (NASDAQ:TLSA, LON:TILS) said it plans to list its diagnostics business Accustem Sciences on the Nasdaq stock market in the US after its demerger and the distribution of new s
Tiziana Life says breast cancer prognostic business Accustem Sciences to list on Nasdaq
08:41am, Tuesday, 13'th Apr 2021
Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distributi
Tiziana Life says breast cancer diagnostic business Accustem Sciences to list on Nasdaq
08:39am, Tuesday, 13'th Apr 2021
Tiziana Life Sciences plc (LON:TILS NASDAQ:TLSA) said its former subsidiary, Accustem Sciences Limited intends to list on Nasdaq. The listing will follow shortly after the completion of the distributi
Zacks Small-Cap Research has started coverage on drug developer Tiziana Life Sciences PLC (NASDAQ:TLSA) (LON:TILS), which is advancing three candidates for a variety of indications in autoimmune disea
Tiziana Life Sciences: US investment bank restates its US$8 price and 'buy' recommendation after double dose of good news
12:26pm, Tuesday, 30'th Mar 2021
US investment bank B. Riley Financial has reiterated its ‘buy' advice and US$8 a share price target for Tiziana Life Sciences (NASDAQ:TLSA, LON:TILS) after a double dose of good news.
